TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01660711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil
Description: 2400 mg/m2 by continuous intravenous infusion over 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 by IV infusion over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
Study: NCT02140801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
Study: NCT01660711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² IV infusion on Day 1 over 2 hours
Study: NCT04300296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg Q4W
Description: secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg Q4W
Description: secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg Q4W
Description: secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg Q2W
Description: secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg Q2W
Description: secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg Q2W
Description: secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered via a pre-filled syringe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered via a pre-filled syringe
Study: NCT01891136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut protein
Description: Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
Study: NCT02364882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Study: NCT02871921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversational Engagement
Description: Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
Study: NCT02365701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motilitone 30mg
Description: 30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
Study: NCT03677973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AB680
Description: AB680 is a Cluster of Differentiation (CD)73 Inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT03140813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (High-Dose)
Description: 15mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (High-Dose)
Description: 15mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (High-Dose)
Description: 15mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (High-Dose)
Description: 15mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (High-Dose)
Description: 15mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (High-Dose)
Description: 15mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (Low-Dose)
Description: 5mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (Low-Dose)
Description: 5mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (Low-Dose)
Description: 5mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (Low-Dose)
Description: 5mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (Low-Dose)
Description: 5mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325 (Low-Dose)
Description: 5mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
Study: NCT04300296

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered via a pre-filled syringe
Study: NCT02378844

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore®-R
Description: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore®-R Sham
Description: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
Study: NCT03431116

Intervention type: RADIATION
Intervention: ultrasound
Description: to detect the placental site
Study: NCT01919424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trudell AeroEclipse*II BAN nebulizer
Description: Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The English-Wright nebulizer
Description: Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada
Study: NCT03509129

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TECH (Technology)
Description: Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.~Device: Fitbit Alta HR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TECH+COMP (Technology + Competition)
Description: Participants will receive the same intervention components as the TECH group, as well as a team competition. The competition will be based on the following two aspects: total daily steps accumulated relative to group size and total number of points retained for achieving weekly physical activity challenges.~Device: Fitbit Alta HR
Study: NCT00463060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate (Sutent)
Description: Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
Study: NCT00701129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alglucosidase Alfa
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered as IV infusion.
Study: NCT00401011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.
Study: NCT01392469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Film coated tablets, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral Administration
Study: NCT00401011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
Study: NCT02412631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin
Description: lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
Study: NCT01392469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Oral Administration
Study: NCT02412631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Chantix is an FDA approved medication for smoking cessation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Chantix is an FDA approved medication for smoking cessation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for lorcaserin
Study: NCT00675857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NC-503 (eprodisate disodium)
Description: capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dosage: 4 capsules BID for 26 weeks
Study: NCT03930459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static cold storage (SCS)
Description: The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
Study: NCT02930538

Intervention type: OTHER
Intervention: Survey
Description: Completing a survey on RedCap
Study: NCT03930459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Description: During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
Study: NCT03287856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
Study: NCT02932891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS topical
Description: topical treatment
Study: NCT02583256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted QIV (aQIV)
Description: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted QIV (aQIV)
Description: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted QIV
Description: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted QIV
Description: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
Study: NCT01530126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B-TCP + 0.3 mg/ml rhPDGF-BB in buffer
Description: B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B-TCP + 1.0 mg/ml rhPDGF-BB in buffer
Description: B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B-TCP +buffer
Description: B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
Study: NCT00546715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Oral Solution, Oral, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Oral Solution, Oral, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Oral Solution, Oral, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Oral Solution, Oral, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, Single Dose
Study: NCT04313920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: 50 g Carbohydrate
Study: NCT03374826

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dedicated axillary hybrid PET-MRI
Description: All clinically node negative patients will undergo a hybrid PET-MRI axilla preoperatively, followed by breast surgery and SLNB.
Study: NCT01993108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: One dose 40mgs of methylphenidate one hour before fMRI scanning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: One dose 40mgs of methylphenidate one hour before fMRI scanning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: One dose 40mgs of naltrexone one hour before fMRI scanning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: One dose 40mgs of naltrexone one hour before fMRI scanning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose of placebo one hour before fMRI scanning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose of placebo one hour before fMRI scanning.
Study: NCT03337633

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menu design
Description: Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menu design
Description: Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menu design
Description: Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menu design
Description: Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.
Study: NCT02346071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services.
Study: NCT00519649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B Kinder
Description: Intramuscular injection, 1 dose
Study: NCT01375218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pavlik Brace
Description: Pavlik Brace

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plastizote Brace
Description: Plastizote Brace
Study: NCT01148628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD 001 in combination with Caelyx
Description: RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
Study: NCT00586677

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-Child Interaction Therapy
Description: Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Safety
Description: Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Relationships
Description: Sixteen one-hour sessions for children age 0-2 provided in-home.